封面
市场调查报告书
商品编码
1304374

品牌非专利市场:医药品分类,各製剂,各适应症,各流通管道,各地区- 市场规模,占有率,展望,机会分析,2023年~2030年

Branded Generics Market, By Drug Class By Formulation, By Indication, Distribution Channel and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 176 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态

ANDA批准的增加是支持市场增长的主要因素。根据德里药物科学研究大学 2023 年 3 月 7 日发表的一篇文章,2022 年期间批准了 742 项 ANDA(简略新药申请),同比增长 17%。此外,还有 136 个临时批准,与最终批准(117 个)一样,与 2021 年相比仍在增长。今年的批准数量比去年增加了88个,印度企业的贡献很大。由于品牌仿製药价格实惠,对仿製药的需求也激增。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间(2022-2030 年)之全球品牌非专利市场的市场规模和復合年增长率(CAGR %)相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会,说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点,各类型投资组合、主要焦点、财务业绩和市场策略等参数,介绍全球品牌非专利市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察,将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球牛血清市场报告配合该行业的各种利益相关者,包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球品牌非专利市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查的目的与前提

  • 调查的目的
  • 前提条件
  • 简称

第2章 市场展望

  • 报告的说明
    • 市场定义和范围
  • 摘要整理
  • 连贯·商机·地图(COM)

第3章 市场动态,法规,趋势分析

  • 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
  • 影响分析
  • 最近的产品销售
  • 流行病学
  • 合併,收购,及的合作
  • 法规情势
  • 主要的发展
  • PEST分析

第4章 品牌非专利的全球市场:COVID-19影响分析

  • 经济影响
  • 新型冠状病毒感染疾病(COVID-19)的流行病学
  • 需求与供给的影响

第5章 品牌非专利的全球市场:医药品分类,2018~2030年

  • 烷化剂
  • 抗代谢物
  • 荷尔蒙
  • 降压剂
  • 脂质低堕胎药
  • 抗忧郁症药
  • 抗精神病药
  • 抗癫痫药
  • 其他

第6章 品牌非专利的全球市场:各製剂,2018~2030年

  • 口服
  • 非口服
  • 讨论价值
  • 其他

第7章 品牌非专利的全球市场:各适应症,2018~2030年

  • 肿瘤学
  • 心血管疾病
  • 糖尿病
  • 神经内科
  • 消化器官疾病
  • 皮肤科的病
  • 止痛药及抗发炎剂
  • 其他

第8章 品牌非专利的全球市场:各流通管道,2018~2030年

  • 医院药局
  • 零售药局
  • 线上药局
  • 药妆店

第9章 品牌非专利的全球市场:各地区,2018~2030年

  • 北美
  • 美国
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他南美国家
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东
  • GCC
  • 以色列
  • 其他中东
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 竞争情形

  • Mylan N.V
    • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aspen Pharmacare Holding Ltd.
  • Abbott Laboratories
  • Valeant Pharmaceuticals International, Inc.

第11章 章节

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI3391

Branded generic is a generic drug, which is manufactured by either original manufacturer after patent expiry of the brand, or is manufactured by a generic manufacturer. Branded generic has to go through abbreviated new drug application (ANDA) process before it can be marketed. Branded generic are cheaper than their branded counterparts but can be costlier than generic versions of the drug. Branded generic is defined as a product that is a novel dosage form of a branded off-patent medicine, and is manufactured by a different manufacturer than originator, or a molecule copy of an off-patent product with a trade name. Branded generics can also be different salts of an FDA-approved brand name drug.

It is easy to confuse branded generics with authorized generics, but they are not the same. Branded generics go through the same FDA approval process as other generics after branded drug patents expire. Authorized generics, however, are created by makers of branded drugs, under the same NDA (New Drug Approval) authorization as the original branded drug, and they may be sold before drug patents expire.

Market Dynamics

Rising ANDA approvals is a major factor which is supporting the market growth. According to an article published by Delhi Pharmaceutical Sciences & Research University on March 7 2023, a total of 742 Abbreviated New Drug Application (ANDA) approvals were granted during the calendar year 2022, registering a growth of 17% over last year. Additionally, 136 Tentative Approvals were also granted, again a similar growth over 2021 numbers (117) as seen for final ANDA approvals. Indian players contributed a large proportion of the incremental number of approvals this year with 88 more approvals than last year. Additionally, demand for generic medications is in surge owing to the affordable prices of branded generics.

Key features of the study:

  • This report provides an in-depth analysis of the global branded generics market and provides market size (US$ Million) and compound annual growth rate (CAGR) of 7.30% for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global branded generics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Aspen Pharmacare Holding Ltd., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global branded generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global branded generics market.

Detailed Segmentation:

  • Global Branded Generics Market, By Drug Class:
    • Alkylating Agents
    • Antimetabolites
    • Hormones
    • Anti-Hypertensive
    • Lipid Lowering Drugs
    • Anti-Depressants
    • Anti-Psychotics
    • Anti-Epileptics
    • Others
  • Global Branded Generics Market, By Formulation:
    • Oral
    • Parenteral
    • Topical
    • Others
  • Global Branded Generics Market, By Indication:
    • Oncology
    • Cardiovascular Diseases
    • Diabetes
    • Neurology
    • Gastrointestinal Diseases
    • Dermatology Diseases
    • Analgesics and Anti-inflammatory
    • Others
  • Global Branded Generics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Drug Stores Global Branded generics Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Mylan N.V*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Aspen Pharmacare Holding Ltd.
    • Abbott Laboratories
    • Valeant Pharmaceuticals International, Inc

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Formulation
    • Market Snapshot, By Indication
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Branded Generics Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Branded Generics Market, By Drug Class, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Alkylating Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Hormones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Hypertensive
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Lipid Lowering Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Depressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Psychotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Epileptics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

6. Global Branded Generics Market, By Formulation, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Branded Generics Market, By Indication, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Cardiovascular Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Gastrointestinal Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Dermatology Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Analgesics and Anti-inflammatory
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Branded Generics Market, By Distribution Channel, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Drug Stores
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

9. Global Branded Generics Market, By Region, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Mylan N.V
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
    • Novartis AG
  • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aspen Pharmacare Holding Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Valeant Pharmaceuticals International, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

11. Section

  • Research Methodology
  • About Us